Equities Analysts Issue Forecasts for CRDL FY2028 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities research analysts at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for Cardiol Therapeutics in a research report issued to clients and investors on Thursday, April 2nd. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.45 per share for the year, up from their prior forecast of $0.38. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2029 earnings at $0.94 EPS and FY2030 earnings at $2.13 EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04.

Separately, raised Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Cardiol Therapeutics Price Performance

Shares of NASDAQ:CRDL opened at $1.41 on Friday. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $1.06 and a two-hundred day moving average of $1.05. The stock has a market cap of $157.67 million, a P/E ratio of -5.04 and a beta of 0.82. Cardiol Therapeutics has a 52-week low of $0.77 and a 52-week high of $1.59.

Institutional Trading of Cardiol Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in shares of Cardiol Therapeutics by 136.2% during the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock valued at $36,000 after buying an additional 15,255 shares during the period. Sheets Smith Investment Management purchased a new position in Cardiol Therapeutics in the third quarter worth approximately $152,000. Two Sigma Investments LP acquired a new stake in Cardiol Therapeutics during the third quarter worth $249,000. Virtu Financial LLC acquired a new stake in Cardiol Therapeutics during the third quarter worth $154,000. Finally, Citadel Advisors LLC raised its position in Cardiol Therapeutics by 1,132.6% in the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after purchasing an additional 425,862 shares during the period. Institutional investors and hedge funds own 12.49% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.